Almirall seeks licensing deals with dozens of Chinese firms
Almirall is in talks with dozens of Chinese firms to license dermatology drugs. CEO Carlos Gallardo noted that high demand is raising upfront payment terms.
Xurve View
Insights:
Xurve View
The pharmaceutical company ALMIRALL SA, headquartered in Spain, is currently engaged in discussions with dozens of firms in China to license rights for various medicines, according to CEO Carlos Gallardo. The company is specifically targeting the medical dermatology sector as it seeks to bolster its portfolio against global competitors.
"I'm sure my team is talking to dozens of companies at this point in time."
